Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Susan I. Colace
Biography
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Research
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Susan I. Colace
Biography
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Research
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Education
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Susan I. Colace
Contact Information
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
Learn more about Susan I. Colace
Biography
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Biography
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Biography
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center. She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Susan Colace, MD, is the Co-Director of the Program for Personalized Medicine and Pharmacogenomics in Pediatric Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital and an Assistant Professor at The Ohio State University College of Medicine. Dr. Colace received her medical degree from Wake Forest University School of Medicine and completed her residency at Children’s Hospital of Alabama. Dr. Colace completed her fellowship training at Monroe Carrell Jr. Children’s Hospital and Vanderbilt University Medical Center.
She is board-certified in general pediatrics, pediatric hematology/oncology and clinical pharmacology. Her research interests include pharmacogenomics, cancer genetics, and chemotherapy toxicities. Clinically, she sees primarily oncology patients with a focus on leukemia and cancer predisposition syndromes.
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Patient Care
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
Locations
Main Campus of Nationwide Children’s Hospital
- Main Campus of Nationwide Children’s Hospital
Academic and Clinical Areas
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Academic and Clinical Areas
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
Cancer Genetics Clinic Team
Medical Director
Hematology/Oncology & BMT
Physician Team
Hematology, Oncology and BMT Fellowship
Faculty
Primary Department
Pediatrics
Primary Section
Hematology & Oncology
- Cancer Genetics Clinic Team
- Medical Director
- Hematology/Oncology & BMT
- Physician Team
- Hematology, Oncology and BMT Fellowship
- Faculty
- Primary Department
- Pediatrics
- Primary Section
- Hematology & Oncology
Research
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Research
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Research
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children's Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
View More Publications
- Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23;
- Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 Jun 21; e29812.
- Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O’Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Am J Hematol. 2022 Feb 18;
- Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer. Methods Mol Biol. 2022; 2547: 63-94.
- Talebi Z, Sparreboom A, Colace SI. Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer. Methods Mol Biol. 2022; 2547: 47-61.
- Rahim MQ, Colace S, Belsky JA. Crossing our Ts: An unusual presentation of infantile T-cell leukemia. Pediatr Blood Cancer. 2021 Dec; 68: e29263.
- Koo SC, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. Genes Chromosomes Cancer. 2021 Sep; 60: 640-646.
- Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 Jun; 11: 1440-1453.
- Brown JT, Ramsey LB, Van Driest SL, Aka I, Colace SI. Characterizing Pharmacogenetic Testing Among Children’s Hospitals. Clin Transl Sci. 2021 Mar; 14: 692-701.
- Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5:
- Ramsey LB, Brown JT, Vear SI, Bishop JR, Van Driest SL. Gene-Based Dose Optimization in Children. Annu Rev Pharmacol Toxicol. 2019 Jul 5;
Education
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Education
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Education
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
Date of Appointment at Nationwide Children’s Hospital: 09/27/2013
Board Certifications
Pediatric Hematology Oncology Pediatrics
Fellowship
Vanderbilt University Medical Center
Date Completed: 06/30/2013
Residency
University of Alabama
Date Completed: 06/30/2009
Medical School
Wake Forest School of Medicine
Date Completed: 05/30/2006
- Pediatric Hematology Oncology
- Pediatrics
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Contact Information
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Pediatrics
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
Call us at: (614) 722-3550
Fax us at: (614) 722-3369
Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
- Call us at:
- (614) 722-3550
- Fax us at:
- (614) 722-3369
- Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)
